By: Emily P. Walker 15 November 2010 WASHINGTON — Merck’s quadrivalent human papillomavirus recombinant vaccine, Gardasil, appears safe and effective at preventing anal cancer in males and females ages 9 to 26, FDA reviewers said. The vaccine was approved in 2006 to treat genital warts and cervical, vulvar, and vaginal cancer in females ages 9 […]
Gardasil Anal Cancer Indication to Face FDA Advisory Committee Scrutiny
By: S. Sutter 27 September 2010 Merck’s bid to further expand the label for its human papillomavirus vaccine Gardasil – this time for the prevention of anal cancer and anal dysplasia – will face FDA advisory committee scrutiny in November. The Vaccines and Related Biological Products Advisory Committee will meet on Nov. 17 to discuss […]
NCI on Cervical Cancer Prevention and HPV vaccines: What’s a Woman to do?
By: Norma Erickson 31 August 2010 The following is a direct quote from a recently revised copy of “Cervical Cancer Prevention, Health Professional Version,” published by the National Cancer Institute (NCI): “The finding of HPV viral DNA integrated in most cellular genomes of cervical carcinomas supports epidemiologic data linking this agent to cervical cancer however, […]
- « Previous Page
- 1
- …
- 33
- 34
- 35